Literature DB >> 11821280

Long term safety of fluoroscopically guided selective salpingography and tubal catheterization.

S Papaioannou1, M Afnan, A Coomarasamy, B Ola, N Hammadieh, D H Temperton, J M McHugo, K Sharif.   

Abstract

BACKGROUND: The irradiation of the ovaries of reproductive age women during fluoroscopically guided selective salpingography and tubal catheterization has raised concern about the safety of the procedure. In addition to the risk of cancer induction, which exists with the irradiation of all tissues, with the gonads, the induction of hereditary disorders is possible. The objective of this study was to estimate these risks and present them in a clinically meaningful way.
METHODS: Retrospective analysis was undertaken of 366 consecutive cases of selective salpingography and tubal catheterization performed at the Birmingham Women's Hospital, UK. The radiation doses of different types of procedure were compared with the background annual radiation dose. The risks of cancer and genetic disorders induction were calculated using conversion coefficients published by the International Commission on Radiological Protection.
RESULTS: The radiation dose women were exposed to during selective salpingography and tubal catheterization under fluoroscopic guidance was a fraction of the background annual radiation dose. The excess lifetime risks of cancer and hereditary disorders were in the order of four to 13 and two to six per million procedures respectively.
CONCLUSIONS: The long term risks of selective salpingography and tubal catheterization under fluoroscopic guidance are low.

Entities:  

Mesh:

Year:  2002        PMID: 11821280     DOI: 10.1093/humrep/17.2.370

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  1 in total

1.  Radiogenic risks from hysterosalpingography.

Authors:  Kostas Perisinakis; John Damilakis; John Grammatikakis; Nicholas Theocharopoulos; Nicholas Gourtsoyiannis
Journal:  Eur Radiol       Date:  2003-02-11       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.